Trial
NCT05172596
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Multiple Myeloma
Intervention
PHE885
Why stopped
The study was terminated since the sponsor made the decision to discontinue further development of the study drug durcabtagene autoleucel (PHE885).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13